Oral treatment is a powerful weapon in the treatment of Covid-19 - More than 8500 patients in Cyprus took the pill
The findings of scientific studies are increasingly encouraging regarding the usefulness of the antiviral treatment Lagevrio (molnupiravir) against Covid 19. Oral treatments to treat the disease are a powerful weapon, especially for people at risk of developing severe disease. Worldwide - and in Cyprus - Lagevrio is indicated for patients with mild to moderate disease.
Interesting evidence comes from a new study (real world experience) conducted in Poland, led by Professor Dr. Robert Flisiak, which evaluated the efficacy of Lagevrio in hospitalized patients during the prevalence of the Omicron SARS-CoV-2 mutation.
Among 11,822 patients hospitalized after March 1, 2020, and included in the SARSTer database maintained by the country, 590 were treated between January 1 and April 30, 2022, the period of Omicron SARS-CoV-2 dominance. The formulation was administered to 203 patients, while 387 did not receive an antiviral regimen. Both groups maintained similar characteristics in terms of sex, body mass index (BMI) and age, allowing direct comparisons.
Patients who did not receive antiviral therapy (in this case Lagevrio) had to be given dexamethasone (dexamethasone) and baricitinib (baricitinib). Treatment with Lagevrio resulted in:
- A statistically significant reduction in mortality during 28-day follow-up (9.9% versus 16.3%), which was particularly evident in the population of patients over 80 years of age treated in the first 5 days of disease (14.6% versus 35.2%).
- The less frequent administration of oxygen supplementation in patients receiving the drug compared to the antiviral-free group (31.7 versus 49.2%).
No difference was observed in terms of hospitalization time between the two groups.
The researchers concluded that the use of Lagevrio reduced mortality, mainly in patients over 80 years of age.
Lagevrio has been available in Cyprus since mid-January and has been prescribed to more than 8,500 patients.
Lagevrio has been available in Cyprus since mid-January and has been prescribed to more than 8,500 patients. Of these, only 5% eventually required hospitalisation for Covid-19. So far, no deaths have been recorded, nor are there any reports of ICU hospitalisation following administration of the drug.
The drug is prescribed to patients with laboratory-confirmed (PCR or Rapid Ag Test) mild or moderate Covid-19 disease, who may develop severe disease, within 5 days from the date of onset of symptoms or date of test. On a protocol basis, prescriptions are filled by adult personal physicians, internists, pulmonologists, hematologists, medical oncologists, cardiologists, nephrologists, nephrologists, neurologists, rheumatologists, endocrinologists, geriatricians and are available from OCYP pharmacies in all cities.
Studies carried out indicate that Lagevrio is effective in reducing hospitalisations and/or deaths by 30%, and especially in the mortality parameter the reduction reaches 89%.
Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times
Source